Related Experiment Video

Updated: Jul 14, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Imatinib effect on growth and signal transduction in polycythemia vera

Amos Gaikwad1, Srdan Verstovsek, Donghoon Yoon

  • 1Department of Pediatric-Hematology-Oncology, Baylor College of Medicine, Houston, Texas, USA.

Experimental Hematology
|May 30, 2007
PubMed
Abstract

Insights

Imatinib effectively inhibits polycythemia vera (PV) cell growth by targeting Janus kinase 2 (JAK2) and STAT5 signaling. This study demonstrates imatinib

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Activating Janus kinase 2 (JAK2) mutations are prevalent in polycythemia vera (PV) and other myeloproliferative disorders.
  • Imatinib is a tyrosine kinase inhibitor with potential therapeutic applications in PV.

Purpose of the Study:

  • To investigate the efficacy of imatinib in PV by examining its effects on JAK2 signaling pathways.
  • To assess imatinib's impact on erythroid progenitors and its correlation with clinical response in PV patients.

Main Methods:

  • Utilized reporter cell lines expressing wild-type and mutant JAK2 (JAK2 V617F) for proliferation and signaling assays.
  • Examined imatinib's effects on in vitro expanded primary human PV erythroid progenitors.
  • Analyzed JAK2 T-allele percentage and phospho-STAT5 levels in PV patients receiving imatinib therapy.

Main Results:

  • Imatinib demonstrated dose- and time-dependent growth inhibition of JAK2 V617F-expressing cells, inactivating JAK2, STAT5, and cKIT.
  • PV erythroid progenitors were more sensitive to imatinib than normal progenitors, with inhibition at achievable in vivo concentrations.
  • A clinical case showed a strong correlation between JAK2 T-allele percentage and imatinib responsiveness.

Conclusions:

  • Imatinib exhibits therapeutic potential in PV by targeting the JAK2/STAT5 and cKIT signaling pathways.
  • This study provides the first evidence of imatinib's direct effects on PV erythroid progenitors.
  • Findings highlight the importance of evaluating drug efficacy in relevant primary cell models alongside cell lines.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...